Molecular Markers for Colorectal Cancer

被引：28
作者：
Wright, Moriah [1 ]
Beaty, Jenifer S. [2 ,3 ]
Ternent, Charles A. [2 ,3 ]
机构：
[1] Colon & Rectal Surg Inc, 9850 Nicholas St,Suite 100, Omaha, NE 68114 USA
[2] CHI Creighton Univ, Med Ctr Bergan Mercy, Dept Surg, 7500 Mercy Rd, Omaha, NE 68124 USA
[3] Univ Nebraska Med Ctr, Dept Surg, 5 42nd St & Emile St, Omaha, NE 68198 USA
来源：
SURGICAL CLINICS OF NORTH AMERICA | 2017年 / 97卷 / 03期
关键词：
Colorectal neoplasm; Drug therapy; Antineoplastic combined chemotherapy; Biomarkers; Tumor/genetics; Antibodies; Monoclonal/therapeutic use; III COLON-CANCER; THYMIDYLATE SYNTHASE INHIBITION; N-TERMINAL KINASE; CD8; T-CELLS; STAGE-II; 1ST-LINE TREATMENT; GENE-EXPRESSION; PHASE-III; MONOCLONAL-ANTIBODY; RANDOMIZED-TRIAL;
D O I：
10.1016/j.suc.2017.01.014
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
Colorectal cancers develop through at least 3 major pathways, including chromosomal instability, mismatch repair, and methylator phenotype. These pathways can coexist in a single individual and occur in both sporadic and inherited colorectal cancers. In spite of the unique molecular and genetic signatures of colorectal cancers, nonspecific chemotherapy based on the antineoplastic effects of 5-fluorouracil is the cornerstone of therapy for stage III and some stage II disease. Techniques to recognize colorectal cancer at the molecular level have facilitated development of new signature drugs designed to inhibit the unique pathways of colorectal cancer growth and immunity.
引用
收藏
页码：683 / +
页数：20
相关论文
共 119 条
  • [1] Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
    Ahmadzadeh, Mojgan
    Johnson, Laura A.
    Heemskerk, Bianca
    Wunderlich, John R.
    Dudley, Mark E.
    White, Donald E.
    Rosenberg, Steven A.
    [J]. BLOOD, 2009, 114 (08) : 1537 - 1544
  • [2] Alcindor T, 2011, CURR ONCOL, V18, P18
  • [3] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    Amado, Rafael G.
    Wolf, Michael
    Peeters, Marc
    Van Cutsem, Eric
    Siena, Salvatore
    Freeman, Daniel J.
    Juan, Todd
    Sikorski, Robert
    Suggs, Sid
    Radinsky, Robert
    Patterson, Scott D.
    Chang, David D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) : 1626 - 1634
  • [4] CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer
    André, T
    Louvet, C
    Maindrault-Goebel, F
    Couteau, C
    Mabro, M
    Lotz, JP
    Gilles-Amar, V
    Krulik, M
    Carola, E
    Izrael, V
    de Gramont, A
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 (09) : 1343 - 1347
  • [5] Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study
    Andre, Thierry
    de Gramont, Armand
    Vernerey, Dewi
    Chibaudel, Benoist
    Bonnetain, Franck
    Tijeras-Raballand, Annemilai
    Scriva, Aurelie
    Hickish, Tamas
    Tabernero, Josep
    Van Laethem, Jean Luc
    Banzi, Maria
    Maartense, Eduard
    Shmueli, Einat
    Carlsson, Goran U.
    Scheithauer, Werner
    Papamichael, Demetris
    Moeehler, Marcus
    Landolfi, Stefania
    Demetter, Pieter
    Colote, Soudhir
    Tournigand, Christophe
    Louvet, Christophe
    Duval, Alex
    Flejou, Jean-Francois
    de Gramont, Aimery
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (35) : 4176 - +
  • [6] Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
    Andre, Thierry
    Boni, Corrado
    Navarro, Matilde
    Tabernero, Josep
    Hickish, Tamas
    Topham, Clare
    Bonetti, Andrea
    Clingan, Philip
    Bridgewater, John
    Rivera, Fernando
    de Gramont, Aimery
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) : 3109 - 3116
  • [7] Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study
    Andreyev, HJN
    Norman, AR
    Cunningham, D
    Oates, JR
    Clarke, PA
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (09) : 675 - 684
  • [8] [Anonymous], 1992, J CLIN ONCOL, V10, P896
  • [9] [Anonymous], P NATL ACAD SCI US
  • [10] Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines
    Arnould, S
    Hennebelle, I
    Canal, P
    Bugat, R
    Guichard, S
    [J]. EUROPEAN JOURNAL OF CANCER, 2003, 39 (01) : 112 - 119
12345678910